The Shopper Walmart Fought Hardest to Win Is Now Eating Less

By year-end 2025, 12.4% of U.S. adults were taking a GLP-1 medication like Ozempic or Wegovy, according to the Gallup National Health and Well-Being Index — more than double the 5.8% share recorded in early 2024, per the same survey. The KFF Health Tracking Poll, conducted in late October 2025, put the figure at roughly one in eight adults, a separate measure that points in the same direction. When Novo Nordisk launched a pill version of Wegovy in January 2026, the remaining friction around injections largely disappeared for the next wave of users, and J.P. Morgan projects more than 30 million Americans will be on a GLP-1 treatment by 2030, up from roughly 10 million today, per CNBC.

For Walmart food suppliers, the scale of that shift matters less than where it is concentrated. The households most likely to be on a GLP-1 drug are the same ones Walmart has spent years and significant capital trying to win, and the data now shows clearly what those households are doing to their grocery baskets.

Walmart Named the Problem in Its Own Earnings Filing

Walmart’s FY25 earnings presentation, filed with the SEC in February 2025, disclosed that GLP-1 drug sales contributed approximately 100 basis points to its full-year Health & Wellness segment comp. CFO John David Rainey attributed mid-teens growth in that segment to branded pharmacy prescriptions, with GLP-1s cited directly. That is a material pharmacy tailwind, and Walmart acknowledged it plainly.

What the filing also showed, in the same category commentary, is that grocery growth was being led by fresh food and that upper-income households were driving share gains. Walmart’s FY26 earnings presentation, filed with the SEC in February 2026, repeated that finding — share gains led by households earning above $100,000. The retailer has celebrated that shift in multiple consecutive earnings periods, and rightly so. Those households represent a meaningful, durable upgrade to the customer mix.

They are also the cohort most likely to be on a GLP-1 medication. Cornell University researchers, publishing in the Journal of Marketing Research in December 2025, analyzed purchase data from a nationally representative panel of roughly 150,000 households tracked by Numerator. Among higher-income GLP-1 users specifically, grocery spending declined more than 8% within six months of starting treatment. The overall household average was 5.3%. The premium cohort Walmart is winning is contracting its food basket faster than the population at large.

The Damage Is Concentrated Exactly Where Suppliers Cannot Afford It

The Cornell study found spending on savory snacks dropped roughly 10% among GLP-1 households, with comparable declines in sweets, baked goods, and cookies. Those categories are not peripheral to most Walmart food suppliers’ business — they are often the highest-velocity, most shelf-space-intensive part of it.

About 70% of GLP-1 users who report consuming fewer calories said they are snacking less, per EY-Parthenon survey data cited by CNBC in March 2026. About half of all GLP-1 users report consuming fewer calories at all, according to UBS Evidence Lab. The distinction matters: the behavioral shift is not universal across every GLP-1 user, but among those showing it, snacking absorbs the sharpest cut.

What is growing inside those same baskets tells suppliers where the category floor is moving. The Cornell data showed yogurt rising the most, followed by fresh fruit, nutrition bars, and meat snacks. Circana’s research, as reported by Grocery Dive in December 2025, projects GLP-1 users will account for more than 35% of total food and beverage sales by 2030. That is not a wellness niche. That is a structural shift in what a meaningful share of the grocery market is willing to buy, and it is already tilting toward protein, fiber, and hydration.

The Merchant Already Has This Data. The Question Is Whether You Do.

Walmart’s category managers are looking at the same purchase signals. Suppliers should expect this dynamic to surface in line reviews and JBP conversations — whether through direct questions about portfolio direction, pack architecture, or the quieter pressure of assortment rationalization in categories that have started to soften.

Suppliers who arrive prepared will have done specific work before the meeting. They will know which of their SKUs index well against GLP-1 consumer behavior and which are directly in the path of declining basket weight. They will have a point of view on pack architecture — whether smaller formats, protein-forward variants, or reformulated options belong in the near-term pipeline. And they will have reviewed Scintilla data for early signals of category softening before the merchant brings it up.

The exposure differs by channel. For 1P suppliers, the risk is a line review conversation where the merchant has already drawn conclusions from the data and a supplier without prepared answers cannot recover in the room. For 3P Marketplace sellers, the pressure is more algorithmic: if Browse behavior on Walmart.com is already shifting toward protein-forward and fiber-rich products, listings built around conventional positioning lose search relevance before the seller notices. Page-one placement in a contracting subcategory does not hold its value.

GLP-1 Adoption Compounds. It Does Not Peak and Reverse.

Not every GLP-1 user represents a permanent reduction in food spending. About 5% of users stop taking the medication in any given period, per CNBC’s March 2026 reporting, and those who discontinue tend to maintain altered eating habits for a couple of months before gradually returning to prior caloric levels. The Cornell study confirmed this: after discontinuation, food spending reverted toward pre-adoption patterns, though users’ baskets became slightly less healthy than before they started, with increased spending in categories like candy and chocolate.

That cycling behavior means the food impact does not resolve cleanly in either direction. It accumulates as new users enter, previous users fluctuate, and total household penetration keeps climbing. Big Chalk Analytics tracked GLP-1 household penetration rising from 11.2% in June 2025 to 12.0% by November 2025. At that pace, millions of additional households shift their purchase behavior each year, and J.P. Morgan estimates the cumulative effect could reduce annual food and beverage industry sales by $30 billion to $55 billion by 2030, per CNBC.

For Walmart suppliers, the planning question is not whether this trend will affect their categories — the Cornell purchase data and Walmart’s own earnings commentary together confirm it already is. The question is whether suppliers bring a portfolio response into the next review or wait for the merchant to ask for one.

Winning With Walmart

Winning With Walmart is an independent platform for suppliers, sellers, solution providers, and industry experts.

Articles are developed by staff editors, contributing experts, and trusted partners.

Some are researched and drafted with the assistance of AI tools and are reviewed, fact-checked, and edited by Winning With Walmart editors before publication.

Editorial judgment, sourcing decisions, and final approval rest with the publication's human editors in every case.

We are committed to accuracy and fairness. If you believe this article contains an error, we welcome your feedback.